CompletedPhase 2

Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma

United Kingdom47 participantsStarted 2008-03

Plain-language summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known which regimen of combination chemotherapy is more effective for Hodgkin lymphoma. PURPOSE: This phase II trial is studying the side effects of three different regimens of combination chemotherapy and to see how well they work in treating younger patients with Hodgkin lymphoma.

Who can participate

Age range18 Years – 30 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Biopsy proven de-novo classical Hodgkin lymphoma * Any stage disease * No nodular lymphocyte-predominant Hodgkin lymphoma PATIENT CHARACTERISTICS: * No known or suspected HIV infection * No pre-existing neurological disorder * No serious comorbidity which may prevent administration of study treatment * No other previous malignancy * Not pregnant or nursing * Fertile patients must use effective contraception during and for up to 1 year after completion of study treatment * Creatinine ≤ 1.5 times upper limit of normal (ULN) unless due to the lymphoma * ALT/AST ≤ 1.5 times ULN unless due to the lymphoma * Bilirubin ≤ 2 times ULN unless due to the lymphoma PRIOR CONCURRENT THERAPY: * No prior chemotherapy or radiotherapy * No prior organ transplant

What they're measuring

Neurotoxicity due to the intensive use of Vinca alkaloids

Timeframe: End of treatment

Trial details

NCT IDNCT00666484

SponsorUniversity College, London

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-09

View on ClinicalTrials.gov More Lymphoma trials